IP Library › Granted Patent US 10,052,353
Granted Patent B2
US 10,052,353 · App. 15/471,493 · Granted Aug 21, 2018

Human-derived bacteria that induce proliferation or accumulation of regulatory T cells

Inventors: Kenya Honda (Tokyo, JP); Koji Atarashi (Tokyo, JP); Takeshi Tanoue (Tokyo, JP); Masahira Hattori (Tokyo, JP); Hidetoshi Morita (Sagamihara, JP)
Assignees: The University of Tokyo; School Corporation, Azabu Veterinary Medicine Educational Institute
A61K35/741A61K9/0053A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,052,353
App. No.
15/471,493
Granted
Aug 21, 2018
Kind
B2
Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

Claims (8)

1. A pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains comprising 16S rDNA sequences of at least 95% homology to SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, or SEQ ID NO:42; and one or more enteric polymers.

2. The composition of claim 1 , wherein the purified bacterial mixture comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 bacterial strains.

3. The composition of claim 1 , wherein the purified bacterial mixture comprises two or more bacterial strains comprising 16S rDNA sequences of at least 95% homology to SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:33, SEQ ID NO:40, or SEQ ID NO:42.

4. The composition of claim 1 , wherein the purified bacterial mixture comprises two or more bacterial strains comprising 16S rDNA sequences of at least 95% homology to SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:32, or SEQ ID NO:41.

5. The pharmaceutical composition of claim 1 , wherein the bacterial strains are human-derived bacteria.

6. The pharmaceutical composition of claim 1 , wherein one or more of the bacterial strains are in spore-form.

7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the intestine or colon.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2017
From: HONDA, KENYA; ATARASHI, KOJI; TANOUE, TAKESHI; HATTORI, MASAHIRA
To: THE UNIVERSITY OF TOKYO
Reel/Frame 041995/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2017
From: MORITA, HIDETOSHI
To: SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION
Reel/Frame 041995/0570 →
Continuity (4)
Continuation 14362097
Provisional Application 61607360 · Mar 6, 2012
Provisional Application 61565976 · Dec 1, 2011
Related Publication 20170209502A1 · Jul 27, 2017
Cited By (3)
US 12,214,003 US 12,409,196 US 12,502,411